Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vidarabine monophosphate
- Development stage
- Unknown
- Lead developer
- Kaifeng Mingren Pharma
- Modality
- Small Molecules
- Administration
- Intravenous, Intramuscular
01
Overview
Vidarabine monophosphate is a small molecule nucleoside analog antiviral agent developed and marketed by Kaifeng Pharma (Kaifeng Mingren Pharmaceutical Co., Ltd.). It is the monophosphate derivative of vidarabine (adenine arabinoside), designed to provide significantly improved water solubility compared to the parent compound, which facilitates its administration as an injection. The drug acts as a prodrug that is intracellularly converted into its active triphosphate form. Once activated, it competitively inhibits viral DNA polymerase, thereby interfering with viral DNA synthesis and replication. In China, it is approved and marketed as a freeze-dried powder for injection for the treatment of various herpes virus infections, including herpes simplex encephalitis, cutaneous and mucosal herpes, and varicella-zoster virus infections.
- Other names
- adenine arabinoside monophosphateAra-AMP单磷酸阿糖腺苷注射用单磷酸阿糖腺苷
02
Targets
HSV DNA pol (Herpes simplex virus DNA polymerase)HSV-TK (Herpes simplex virus type 1 thymidine kinase (HSV1-TK))POLA1 (DNA polymerase alpha)POLB (DNA polymerase beta)RNR (Ribonucleotide reductase)DNTT (Terminal deoxynucleotidyl transferase)Herpesvirus DNA polymeraseDNA polymerase family
Beyond the preview
Go deeper on vidarabine monophosphate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vidarabine monophosphate.